GABA receptor subunit distribution and FMRP–mGluR5 signaling abnormalities in the cerebellum of subjects with schizophrenia, mood disorders, and autism
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Gamma-aminobutyric acid (GABA) is the main inhibitory neurotransmitter in the brain. GABAergic receptor abnormalities have been documented in several major psychiatric disorders including schizophrenia, mood disorders, and autism. Abnormal expression of mRNA and protein for multiple GABA receptors has also been observed in multiple brain regions leading to alterations in the balance between excitatory/inhibitory signaling in the brain with potential profound consequences for normal cognition and maintenance of mood and perception. Altered expression of GABAA receptor subunits has been documented in Fragile X mental retardation 1 (FMR1) knockout mice, suggesting that loss of its protein product, fragile X mental retardation protein (FMRP), impacts GABAA subunit expression. Recent postmortem studies from our laboratory have shown reduced expression of FMRP in brains of subjects with schizophrenia, bipolar disorder, major depression, and autism. FMRP acts as a translational repressor and, under normal conditions, inhibits metabotropic glutamate receptor 5 (mGluR5)-mediated signaling. In fragile X syndrome (FXS), absence of FMRP is hypothesized to lead to unregulated mGluR5 signaling, ultimately resulting in the behavioral and intellectual impairments associated with this disorder. Our laboratory has identified changes in mGluR5 expression in autism, schizophrenia, and mood disorders. In the current review article, we discuss our postmortem data on GABA receptors, FMRP, and mGluR5 levels and compare our results with other laboratories. Finally, we discuss the interactions between these molecules and the potential for new therapeutic interventions that target these interconnected signaling systems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FMRP Stalls Ribosomal Translocation on mRNAs Linked to Synaptic Function and Autism
Darnell, J. C., Van Driesche, S. J., Zhang, C., Hung, K. Y. S., Mele, A., Fraser, C. E., Stone, E. F., Chen, C., Fak, J. J., Chi, S. W., et al. (2011) · Cell · doi:10.1016/j.cell.2011.06.013 · Cited by 2,072 · cited 5×
“FMRP has been shown to directly bind GABBR1, GABBR2, and GABRδ mRNAs (Darnell et al., 2011; Miyashiro et al., 2003) while no direct binding of FMRP to mRNAs for GABRα1-α6, GABRβ1-β3, or GABRγ1-γ3 has been demonstrated (Brown et al.”
BackgroundInfluentialDe novo mutations in schizophrenia implicate synaptic networks
Fromer, M., Pocklington, A. J., Kavanagh, D. H., Williams, H. J., Dwyer, S., Gormley, P., Georgieva, L., Rees, E., Palta, P., Ruderfer, D. M., et al. (2014) · Nature · doi:10.1038/nature12929 · Cited by 1,617
The mGluR theory of fragile X mental retardation
Bear, M. F., Huber, K. M., & Warren, S. T. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.04.009 · Cited by 1,580 · cited 3×
“As mentioned previously, in the absence of FMRP, unregulated mGluR5 signaling is believed to lead to the intellectual impairment associated with FXS (Bear et al., 2004; Schizophr Res.”
BackgroundAbsence of expression of the FMR-1 gene in fragile X syndrome
Pieretti, M., Zhang, F., Fu, Y.-H., Warren, S. T., Oostra, B. A., Caskey, C. T., & Nelson, D. L. (1991) · Cell · doi:10.1016/0092-8674(91)90125-i · Cited by 1,476
De Novo Gene Disruptions in Children on the Autistic Spectrum
Iossifov, I., Ronemus, M., Levy, D., Wang, Z., Hakker, I., Rosenbaum, J., Yamrom, B., Lee, Y.-H., Narzisi, G., Leotta, A., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.04.009 · Cited by 1,446 · cited 1×
“Lastly, recent positive associations between FMRP target mutations in schizophrenia and autism (Fromer et al., 2014; Iossifov et al., 2012; Purcell et al., 2014) clearly expand the pathological role of FMRP in these diseases.”
BackgroundA polygenic burden of rare disruptive mutations in schizophrenia
Purcell, S. M., Moran, J. L., Fromer, M., Ruderfer, D., Solovieff, N., Roussos, P., O’Dushlaine, C., Chambert, K., Bergen, S. E., Kähler, A., et al. (2014) · Nature · doi:10.1038/nature12975 · Cited by 1,385 · cited 2×
“…that FMRP targets including calcium/calmodulin-dependent protein kinase II alpha and beta (CAMK2A and CAMK2B), aconitase, mitochondrial (ACO2), and calcium channel, voltage-dependent, N-type, alpha 1B subunit (CACNA1B) were identified as particularly enriched for mutations (Purcell et al., 2014).”
BackgroundNeurosteroids: endogenous regulators of the GABAA receptor
Belelli, D., & Lambert, J. J. (2005) · Nature reviews. Neuroscience · doi:10.1038/nrn1703 · Cited by 1,159 · cited 1×
“…extrasynaptic receptors the presence of the δ subunit are insensitive to benzodiazepines but are sensitive to the agonist 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol (THiP or Gaboxadol; Wafford and Ebert, 2006) as well as neurosteroids (Stell et al., 2003; Belelli and Lambert, 2005).”
BackgroundBrown, V., Jin, P., Ceman, S., Darnell, J. C., O'Donnell, W. T., Tenenbaum, S. A., Jin, X., Feng, Y., Wilkinson, K. D., Keene, J. D., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00568-2 · Cited by 1,109 · cited 2×
“, 2003) while no direct binding of FMRP to mRNAs for GABRα1-α6, GABRβ1-β3, or GABRγ1-γ3 has been demonstrated (Brown et al., 2001; Chen et al., 2003; Darnell et al., 2011).”
BackgroundThe GABAergic deficit hypothesis of major depressive disorder
Luscher, B., Shen, Q., & Sahir, N. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.120 · Cited by 934
Decreased GABAA-receptor clustering results in enhanced anxiety and a bias for threat cues
Crestani, F., Lorez, M., Baer, K., Essrich, C., Benke, D., Laurent, J. P., Belzung, C., Fritschy, J.-M., Lüscher, B., & Mohler, H. (1999) · Nature Neuroscience · doi:10.1038/12207 · Cited by 550 · cited 2×
“Mice with selective heterozygous deletion of GABRγ2, display increased immobility following the forced swim test or the novelty-suppressed feeding test (Earnheart et al., 2007) and exhibit increased anxiety (Crestani et al., 1999).”
BackgroundRNA cargoes associating with FMRP reveal deficits in cellular functioning in Fmr1 null mice
Miyashiro, K. Y., Beckel-Mitchener, A., Purk, T. P., Becker, K. G., Barret, T., Liu, L., Carbonetto, S., Weiler, I. J., Greenough, W. T., & Eberwine, J. (2003) · Neuron · doi:10.1016/s0896-6273(03)00034-5 · Cited by 495
The translation of translational control by FMRP: therapeutic targets for FXS
Darnell, J. C., & Klann, E. (2013) · Nature Neuroscience · doi:10.1038/nn.3379 · Cited by 491 · cited 3×
“Expression of FMRP-mGluR5 Molecular Targets in Schizophrenia, Mood Disorders and Autism In addition to some of the GABA receptors, a number of important molecules are targets of FMRP-mGluR5 signaling and synaptic transmission (Darnell et al., 2011; Darnell and Klann, 2013).”
BackgroundHashimoto, T., Arion, D., Unger, T., Maldonado-Avilés, J. G., Morris, H. M., Volk, D. W., Mirnics, K., & Lewis, D. A. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002011 · Cited by 490
Hou, L., Antion, M. D., Hu, D., Spencer, C. M., Paylor, R., & Klann, E. (2006) · Neuron · doi:10.1016/j.neuron.2006.07.005 · Cited by 469 · cited 2×
“, 2005), altered long-term depression (Hou et al., 2006), and an increase in long, immature dendritic spines (Irwin et al.”
BackgroundGABAA Receptor Downregulation in Brains of Subjects with Autism
Fatemi, S. H., Reutiman, T. J., Folsom, T. D., & Thuras, P. D. (2009) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-008-0646-7 · Cited by 439
Self-citationA pilot open label, single dose trial of fenobam in adults with fragile X syndrome
Berry-Kravis, E., Hessl, D., Coffey, S., Hervey, C., Schneider, A., Yuhas, J., Hutchison, J., Snape, M., Tranfaglia, M., Nguyen, D. V., et al. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.063701 · Cited by 411 · cited 1×
“Fenobam, an antagonist of mGluR5 was shown to improve PPI deficits in six out of 12 subjects with FXS in a pilot study (Berry-Kravis et al., 2009).”
BackgroundLevkovitz, Y., Mendlovich, S., Riwkes, S., Braw, Y., Levkovitch-Verbin, H., Gal, G., Fennig, S., Treves, I., & Kron, S. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04666yel · Cited by 387 · cited 2×
“…trials of minocycline in subjects with schizophrenia have demonstrated a beneficial effect on the negative symptoms, and cognitive functioning (Levkovitz et al., 2010; Miyaoka et al., 2008). mGluR5 negative allosteric modulator 2-Methyl-6-(phenylethynyl)pyridine (MPEP) has shown promise in…”
BackgroundDeng, P.-Y., Rotman, Z., Blundon, J. A., Cho, Y., Cui, J., Cavalli, V., Zakharenko, S. S., & Klyachko, V. A. (2013) · Neuron · doi:10.1016/j.neuron.2012.12.018 · Cited by 354
Blatt, G. J., Fitzgerald, C. M., Guptill, J. T., Booker, A. B., Kemper, T. L., & Bauman, M. L. (2001) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1013238809666 · Cited by 322 · cited 2×
“Reduced 3H-muscimol-labeled GABAA receptor binding sites and 3H-flunitrazepam-labeled benzodiazepine binding sites have been found in hippocampus of subjects with autism (Blatt et al., 2001).”
BackgroundDecreased expression of the GABAA receptor in fragile X syndrome
D'Hulst, C., De Geest, N., Reeve, S. P., Van Dam, D., De Deyn, P. P., Hassan, B. A., & Kooy, R. F. (2006) · Brain Research · doi:10.1016/j.brainres.2006.08.115 · Cited by 318 · cited 8×
“Data from animal models of fragile X syndrome (FXS), which lack FMRP (an RNA binding master protein that targets 5% of all brain genes including some of the GABA receptors) show altered expression of GABA receptor subunits in brain (Adusei et al., 2010; El Idrissi et al., 2005; D’Hulst et al., 2006; Gantois et al., 20…”
BackgroundResultInfluentialRescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice
de Vrij, F. M. S., Levenga, J., van der Linde, H. C., Koekkoek, S. K., De Zeeuw, C. I., Nelson, D. L., Oostra, B. A., & Willemsen, R. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.04.002 · Cited by 313
Olmos-Serrano, J. L., Paluszkiewicz, S. M., Martin, B. S., Kaufmann, W. E., Corbin, J. G., & Huntsman, M. M. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.1714-10.2010 · Cited by 309
Deschwanden, A., Karolewicz, B., Feyissa, A. M., Treyer, V., Ametamey, S. M., Johayem, A., Burger, C., Auberson, Y. P., Sovago, J., Stockmeier, C. A., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.09111607 · Cited by 278
Irwin, S. A., Idupulapati, M., Gilbert, M. E., Harris, J. B., Chakravarti, A. B., Rogers, E. J., Crisostomo, R. A., Larsen, B. P., Mehta, A., Alcantara, C. J., et al. (2002) · American Journal of Medical Genetics · doi:10.1002/ajmg.10500 · Cited by 270 · cited 2×
“As a result there is increased synthesis of synaptic proteins (Weiler and Greenough, 1999) which results in increased epileptiform discharges (Chuang et al., 2005), altered long-term depression (Hou et al., 2006), and an increase in long, immature dendritic spines (Irwin et al., 2002).”
BackgroundHenderson, C., Wijetunge, L., Kinoshita, M. N., Shumway, M., Hammond, R. S., Postma, F. R., Brynczka, C., Rush, R., Thomas, A., Paylor, R., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004218 · Cited by 249 · cited 2×
“…allosteric modulators of GABAA receptors (ganaxolone) or GABAB receptors (arbaclofen) rescued many FXS-related deficits in FMR1 KO mice including reducing audiogenic seizures, spine density, protein synthesis, and internalization of AMPA receptors (Henderson et al., 2012; Heulens et al., 2012).”
BackgroundPinna, G., Costa, E., & Guidotti, A. (2006) · Psychopharmacology · doi:10.1007/s00213-005-0213-2 · Cited by 245 · cited 1×
“…synaptic transmission has been associated with panic, anxiety, impaired learning and memory, and sleep abnormalities (Heulens et al., 2010; Pinna et al., 2006, 2009), and thus contributes to deficits associated with schizophrenia, bipolar disorder, major depression, and autism…”
BackgroundExpression of GABAB Receptors Is Altered in Brains of Subjects with Autism
Fatemi, S. H., Folsom, T. D., Reutiman, T. J., & Thuras, P. D. (2009) · The Cerebellum · doi:10.1007/s12311-008-0075-3 · Cited by 227 · cited 12×
“In BA40 of subjects with autism, we determined that both mRNA and protein levels for GABRα3 were significantly reduced (Fatemi et al., 2009a, 2014) (Table 1).”
BackgroundInfluentialSelf-citationOpen-label add-on treatment trial of minocycline in fragile X syndrome.
Paribello, C., Tao, L., Folino, A., Berry-Kravis, E., Tranfaglia, M., Ethell, I. M., & Ethell, D. W. (2010) · BMC Neurology · doi:10.1186/1471-2377-10-91 · Cited by 223 · cited 1×
“Treatment with minocycline has been shown to improve behavior in subjects with FXS (Paribello et al., 2010).”
BackgroundGandal, M. J., Sisti, J., Klook, K., Ortinski, P. I., Leitman, V, Liang, Y., Thieu, T., Anderson, R., Pierce, R. C., Jonak, G., et al. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.69 · Cited by 204 · cited 1×
“Baclofen, another GABAB receptor agonist, has been shown to reverse deficits in social interaction and spatial working memory (Gandal et al., 2012).”
BackgroundEarnheart, J. C., Schweizer, C., Crestani, F., Iwasato, T., Itohara, S., Mohler, H., & Lüscher, B. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3609-06.2007 · Cited by 203 · cited 2×
“Mice with selective heterozygous deletion of GABRγ2, display increased immobility following the forced swim test or the novelty-suppressed feeding test (Earnheart et al., 2007) and exhibit increased anxiety (Crestani et al., 1999).”
BackgroundDecreased GABA B receptors in the cingulate cortex and fusiform gyrus in Autism
Oblak, A. L., Gibbs, T. T., & Blatt, G. J. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06858.x · Cited by 203
Yee, B. K., Keist, R., von Boehmer, L., Studer, R., Benke, D., Hagenbuch, N., Dong, Y., Malenka, R. C., Fritschy, J.-M., Bluethmann, H., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508752102 · Cited by 201
Marx, C. E., Keefe, R. S. E., Buchanan, R. W., Hamer, R. M., Kilts, J. D., Bradford, D. W., Strauss, J. L., Naylor, J. C., Payne, V. M., Lieberman, J. A., et al. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.26 · Cited by 193
Fatemi, S. H., Reutiman, T. J., Folsom, T. D., Rooney, R. J., Patel, D. H., & Thuras, P. D. (2010) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-009-0924-z · Cited by 182 · cited 22×
“In BA40 of subjects with autism, we determined that both mRNA and protein levels for GABRα3 were significantly reduced (Fatemi et al., 2009a, 2014) (Table 1).”
BackgroundInfluentialSelf-citationFragile X: Leading the Way for Targeted Treatments in Autism
Wang, L. W., Berry-Kravis, E., & Hagerman, R. J. (2010) · Neurotherapeutics · doi:10.1016/j.nurt.2010.05.005 · Cited by 176
Duncan, C. E., Webster, M. J., Rothmond, D. A., Bahn, S., Elashoff, M., & Shannon Weickert, C. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2009.12.007 · Cited by 169
Chen, L., Yun, S.-W., Seto, J., Liu, W., & Toth, M. (2003) · Neuroscience · doi:10.1016/s0306-4522(03)00406-8 · Cited by 160 · cited 1×
“FMRP has been shown to directly bind GABBR1, GABBR2, and GABRδ mRNAs (Darnell et al., 2011; Miyashiro et al., 2003) while no direct binding of FMRP to mRNAs for GABRα1-α6, GABRβ1-β3, or GABRγ1-γ3 has been demonstrated (Brown et al., 2001; Chen et al., 2003; Darnell et al., 2011).”
BackgroundPinna, G., Costa, E., & Guidotti, A. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.12.006 · Cited by 156 · cited 1×
“…synaptic transmission has been associated with panic, anxiety, impaired learning and memory, and sleep abnormalities (Heulens et al., 2010; Pinna et al., 2006, 2009), and thus contributes to deficits associated with schizophrenia, bipolar disorder, major depression, and autism…”
BackgroundMinocycline as Adjunctive Therapy for Schizophrenia: An Open-Label Study
Miyaoka, T., Yasukawa, R., Yasuda, H., Hayashida, M., Inagaki, T., & Horiguchi, J. (2008) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181593d45 · Cited by 146 · cited 2×
“Preliminary trials of minocycline in subjects with schizophrenia have demonstrated a beneficial effect on the negative symptoms, and cognitive functioning (Levkovitz et al., 2010; Miyaoka et al., 2008).”
BackgroundEarly developmental alterations in GABAergic protein expression in fragile X knockout mice
Adusei, D. C., Pacey, L. K. K., Chen, D., & Hampson, D. R. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.05.002 · Cited by 139
Nalavadi, V. C., Muddashetty, R. S., Gross, C., & Bassell, G. J. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5057-11.2012 · Cited by 128
A Randomized, Double-Blind, Placebo-Controlled Trial of Pregnenolone for Bipolar Depression
Brown, E. S., Park, J., Marx, C. E., Hynan, L. S., Gardner, C., Davila, D., Nakamura, A., Sunderajan, P., Lo, A., & Holmes, T. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.138 · Cited by 96 · cited 1×
“A recent double-blind, placebo-controlled trial of pregnenolone in subjects with bipolar disorder found that it was effective in treating depressive symptoms in this population (Brown et al., 2014).”
BackgroundAntidepressant-like properties of α2-containing GABAA receptors
Vollenweider, I., Smith, K. S., Keist, R., & Rudolph, U. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.10.009 · Cited by 96 · cited 2×
“, increased immobility) in response to the forced swim test (FST) and the tail suspension test (TST) (Vollenweider et al., 2011).”
BackgroundMaldonado-Avilés, J. G., Curley, A. A., Hashimoto, T., Morrow, A. L., Ramsey, A. J., O’Donnell, P., Volk, D. W., & Lewis, D. A. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08101484 · Cited by 91
Ritsner, M. S., Gibel, A., Shleifer, T., Boguslavsky, I., Zayed, A., Maayan, R., Weizman, A., & Lerner, V. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05031yel · Cited by 85 · cited 2×
“Pregnenolone has recently shown promise in ameliorating positive, negative, and cognitive deficits in schizophrenia (Kreinin et al., 2014; Marx et al., 2009; Ritsner et al., 2010, 2014).”
BackgroundFatemi, S. H., & Folsom, T. D. (2011) · Molecular Autism · doi:10.1186/2040-2392-2-6 · Cited by 84
Self-citationGerdjikov, T. V., Rudolph, U., Keist, R., Möhler, H., Feldon, J., & Yee, B. K. (2008) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2007.06.003 · Cited by 43
Cited by
The GABAA Receptor as a Therapeutic Target for Neurodevelopmental Disorders
Braat, S., & Kooy, R. F. (2015) · Neuron · doi:10.1016/j.neuron.2015.03.042 · Cited by 294
Fetit, R., Hillary, R. F., Price, D. J., & Lawrie, S. M. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.07.014 · Cited by 148
The Fragile Brain: Stress Vulnerability, Negative Affect and GABAergic Neurocircuits in Psychosis
Taylor, S. F., Grove, T. B., Ellingrod, V. L., & Tso, I. F. (2019) · Schizophrenia Bulletin · doi:10.1093/schbul/sbz046 · Cited by 67
Metadata
- Authors
- Fatemi, S. H., & Folsom, T. D.
- Venue
- Schizophrenia Research
- Publisher
- Elsevier BV
- Published
- 2015-09
- Volume
- 167
- Issue
- 1-3
- Pages
- 42-56
- ISSN
- 0920-9964 (ISSN-L)
- OpenAlex
- W2043010186
- Cited by
- 85
- References
- 47
- FWCI
- 4.75
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.